Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02114606 · ClinicalTrials.gov registry record · NA

Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge

A NA study, sponsored by University of North Carolina, Chapel Hill.

Terminated
Registry status
NA
Development phase
86
Enrollment target

NCT02114606 is a NA study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 86 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02114606, a NA study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.

TERMINATED
Registry status
NA
Development phase
86 participants
Enrollment target

Study Summary

The current endoscopic methods for diagnosing and monitoring treatment response in Eosinophilic Esophagitis (EoE) are costly, inconvenient, and risky. Novel diagnostic methods are needed, and the minimally-invasive Cytosponge holds great promise. It has been shown to be safe and accurate in Barrett's esophagus, it has the advantage (over the string test) of obtaining a true tissue sample, and our preliminary data supports its further study in EoE. The proposed prospective cohort study, conducted by experts in esophageal diseases and EoE, will assess the accuracy of Cytosponge compared to endoscopy and biopsy in EoE, and determine the safety and acceptability of this technique. Use of the Cytosponge would fundamentally change the paradigm for clinical management of EoE by allowing collection of non-endoscopic esophageal biopsies, thus minimizing the need for invasive testing. It would also facilitate future genetic, mechanistic, and pathogenesis research in EoE.

Interventions

  • DEVICE Cytosponge™ Cell Collection Device

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2015-07
Est. Completion 2016-06
Phase NA

What the Registry Record Tells You About NCT02114606

The ClinicalTrials.gov registry entry for NCT02114606 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Cytosponge™ Cell Collection Device is the first listed.

NCT02114606 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02114606 about?

NCT02114606 is a clinical study titled "Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge". The current endoscopic methods for diagnosing and monitoring treatment response in Eosinophilic Esophagitis (EoE) are costly, inconvenient, and risky. Novel diagnostic methods are needed, and the minimally-invasive Cytosponge holds great promise. It has been shown to be safe and accurate in Barrett'...

What is the current status of trial NCT02114606?

This trial is currently terminated. It is a NA study. The enrollment target is 86 participants. The study started on 2015-07. Estimated completion is 2016-06.

What interventions are being tested in trial NCT02114606?

The interventions under investigation include: Cytosponge™ Cell Collection Device (DEVICE).

Who is sponsoring clinical trial NCT02114606?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.